zacks.com · 14 jul

Is AtaiBeckley Inc (ATAI) Stock Outpacing Its Medical Peers This Year?

Here is how AtaiBeckley Inc (ATAI) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

proactiveinvestors.com · 14 jul

CleanSpark shares surge after company secures $6.6B data center lease agreement

CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...

proactiveinvestors.com · 14 jul

Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacity

Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...

proactiveinvestors.com · 13 jul

Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says

The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Cybin Inc. (NYSE-A:CYBN, FRA:R7E), GH Research (NASDAQ:GHRS), Awakn Life Sciences (NEO:AWKN) and others in the sector. The firm wrote on Monday that the final guidance, alongside the FDA's plans to hold a public hearing on September 14, points to a more supportive regulatory environment that could reduce regulatory risk for psychedelic drug developers.

fool.com · 9 jul

What This $496,000 Insider Sale at AtaiBeckley Means Amid Roughly 100% Stock Run

This disposal of 100,000 shares was executed at $4.96 per share, generating gross proceeds of $496,000 on July 7, 2026. The transaction reduced Hershberg direct equity position by 50% through the sale of shares in the open market.

proactiveinvestors.com · 8 jul

FuelCell Energy shares fall after company prices upsized $225M stock offering

FuelCell Energy (NASDAQ:FCEL) shares declined on Wednesday after the company priced an upsized public offering of common stock, raising concerns among...

proactiveinvestors.com · 8 jul

Dow Jones and Nasdaq start lower as Trump says Iran ceasefire 'over'

10am: Wall Street starts in the red Wall Street stocks have mostly opened in the red, after government bond yields climbed to around a seven-week high...

proactiveinvestors.com · 7 jul

AtaiBeckley set to unlock value from positive depression therapy trial results, says Jefferies

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) could see increased investor attention as it approaches Phase IIb data for its oral DMT-based therapy VLS-01, according to Jefferies analysts, who highlighted the program's potential to add value to the company's psychedelic medicine pipeline. The analysts wrote that VLS-01's completed Phase IIb enrollment in treatment-resistant depression (TRD) sets up a fourth quarter 2026 topline data readout, which could serve as a potential de-risking event for the program.